Deltex Medical Group plc
DTXMF · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $0 | $1 |
| % Growth | -6.8% | 196.8% | -66.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $1 | $0 | $1 |
| % Margin | 69.3% | 66.8% | 9.9% | 66.9% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $1 | $0 | $0 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $0 | $0 | $0 |
| Operating Expenses | $2 | $1 | $1 | $1 |
| Operating Income | -$1 | -$0 | -$0 | -$1 |
| % Margin | -115.3% | -41.5% | -111.9% | -51.6% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | $0 |
| Pre-Tax Income | -$1 | -$1 | -$1 | -$1 |
| Tax Expense | $0 | $0 | -$0 | -$0 |
| Net Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | -126.1% | -51.3% | -200.6% | -50.8% |
| EPS | -0.001 | -0 | -0 | -0.001 |
| % Growth | -133.3% | 25% | 50% | – |
| EPS Diluted | -0.001 | -0 | -0 | -0.001 |
| Weighted Avg Shares Out | 1,898 | 1,896 | 1,663 | 705 |
| Weighted Avg Shares Out Dil | 1,896 | 1,892 | 1,659 | 703 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | -$0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -40.7% | -37.9% | -34.3% | -14.2% |